Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
37 drugs in development
By Therapeutic Area
top 4
R&D Momentum
91/100
Pipeline Velocity
63/100
Trial Completion Rate
85/100
Pipeline Concentration
53/100
Pipeline Freshness
66/100
Strategic Signals
Activity
Last 14 days
Clinical Trial of an Upper Limb Measurement Device
Neoadjuvant Pyrotinib Combined With Chemotherapy Versus Chemotherapy in HR-positive/HER2-low (IHC 2+/FISH-negative) High-risk Early Breast Cancer: an Open-lable, Multi-center, Randomized Phase III Trial
Feasibility Evaluation of the "One-Finger Technique" for Dissecting and Identifying the Upper Left Ureter During Para-Aortic Lymphadenectomy: A Prospective, Single-Center, Single-Arm Clinical Study
A Phase II, Open-Label, Randomized Study Comparing Antiangiogenic Therapy Combined With Immunotherapy and Capecitabine Versus Investigator's Choice in Patients With Circulating Tumor DNA-Positive Stage II-III Triple-Negative Breast Cancer Who With Residual Disease After Neoadjuvant Therapy
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)